Cargando…

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

BACKGROUND: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have been associated with the increased likelihood of developing adverse CNS effects. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Gounden, Verena, van Niekerk, Chantal, Snyman, Tracy, George, Jaya A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933581/
https://www.ncbi.nlm.nih.gov/pubmed/20723261
http://dx.doi.org/10.1186/1742-6405-7-32
_version_ 1782186151400964096
author Gounden, Verena
van Niekerk, Chantal
Snyman, Tracy
George, Jaya A
author_facet Gounden, Verena
van Niekerk, Chantal
Snyman, Tracy
George, Jaya A
author_sort Gounden, Verena
collection PubMed
description BACKGROUND: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have been associated with the increased likelihood of developing adverse CNS effects. The aims of this study were to a) determine the presence of the 516G > T and other CYP2B6 exon 4 polymorphisms in a South African group of HIV-infected individuals b) investigate the relationship between the EFV plasma concentrations, the CYP2B6 516G > T polymorphism and the occurrence of CNS related side effects in this group of patients and c) develop and validate a rapid method for determination of EFV in plasma. METHOD: Data from 80 patients is presented. Genetic polymorphisms in exon 4 of the CYP2B6 gene were identified using PCR amplification of this region followed by sequencing of the amplification products. EFV concentrations were analysed by UPLC-MS/MS. Assessment of the presence of CNS related side effects following EFV initiation were elicited with the use of a questionnaire together with physical examination. RESULTS: Plasma EFV concentrations displayed high inter-individual variability amongst subjects with concentrations ranging from 94 μg/l to 23227 μg/l at 2 weeks post initiation of treatment. For the 516G > T polymorphism the following frequencies were observed 23% of patients were TT homozygous, 36% GG and 41% GT. The TT homozygous patients had significantly higher EFV concentrations vs. those with the wild (GG) genotype (p < 0.05). Patients who experienced no side effects had significantly lower EFV plasma concentrations vs. the group of patients which experienced the most severe side effects (p < 0.05). CONCLUSION: The significant association between the 516G > T polymorphism and plasma EFV concentrations has been demonstrated in this study. A rapid and sensitive method for the measurement of plasma EFV concentration was developed and validated.
format Text
id pubmed-2933581
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29335812010-09-07 Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients Gounden, Verena van Niekerk, Chantal Snyman, Tracy George, Jaya A AIDS Res Ther Research BACKGROUND: The 516G > T polymorphism in exon 4 of the CYP2B6 gene has been associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations greater than the recommended therapeutic range have been associated with the increased likelihood of developing adverse CNS effects. The aims of this study were to a) determine the presence of the 516G > T and other CYP2B6 exon 4 polymorphisms in a South African group of HIV-infected individuals b) investigate the relationship between the EFV plasma concentrations, the CYP2B6 516G > T polymorphism and the occurrence of CNS related side effects in this group of patients and c) develop and validate a rapid method for determination of EFV in plasma. METHOD: Data from 80 patients is presented. Genetic polymorphisms in exon 4 of the CYP2B6 gene were identified using PCR amplification of this region followed by sequencing of the amplification products. EFV concentrations were analysed by UPLC-MS/MS. Assessment of the presence of CNS related side effects following EFV initiation were elicited with the use of a questionnaire together with physical examination. RESULTS: Plasma EFV concentrations displayed high inter-individual variability amongst subjects with concentrations ranging from 94 μg/l to 23227 μg/l at 2 weeks post initiation of treatment. For the 516G > T polymorphism the following frequencies were observed 23% of patients were TT homozygous, 36% GG and 41% GT. The TT homozygous patients had significantly higher EFV concentrations vs. those with the wild (GG) genotype (p < 0.05). Patients who experienced no side effects had significantly lower EFV plasma concentrations vs. the group of patients which experienced the most severe side effects (p < 0.05). CONCLUSION: The significant association between the 516G > T polymorphism and plasma EFV concentrations has been demonstrated in this study. A rapid and sensitive method for the measurement of plasma EFV concentration was developed and validated. BioMed Central 2010-08-19 /pmc/articles/PMC2933581/ /pubmed/20723261 http://dx.doi.org/10.1186/1742-6405-7-32 Text en Copyright ©2010 Gounden et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gounden, Verena
van Niekerk, Chantal
Snyman, Tracy
George, Jaya A
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title_full Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title_fullStr Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title_full_unstemmed Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title_short Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
title_sort presence of the cyp2b6 516g> t polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in south african hiv-infected patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933581/
https://www.ncbi.nlm.nih.gov/pubmed/20723261
http://dx.doi.org/10.1186/1742-6405-7-32
work_keys_str_mv AT goundenverena presenceofthecyp2b6516gtpolymorphismincreasedplasmaefavirenzconcentrationsandearlyneuropsychiatricsideeffectsinsouthafricanhivinfectedpatients
AT vanniekerkchantal presenceofthecyp2b6516gtpolymorphismincreasedplasmaefavirenzconcentrationsandearlyneuropsychiatricsideeffectsinsouthafricanhivinfectedpatients
AT snymantracy presenceofthecyp2b6516gtpolymorphismincreasedplasmaefavirenzconcentrationsandearlyneuropsychiatricsideeffectsinsouthafricanhivinfectedpatients
AT georgejayaa presenceofthecyp2b6516gtpolymorphismincreasedplasmaefavirenzconcentrationsandearlyneuropsychiatricsideeffectsinsouthafricanhivinfectedpatients